These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27470558)

  • 1. The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis.
    Gao T; Mei Y; Sun H; Nie Z; Liu X; Wang S
    Biomed Pharmacother; 2016 Oct; 83():114-121. PubMed ID: 27470558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
    Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
    BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
    Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
    Liu R; Zhou J; Xia S; Li T
    Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.
    Kluth M; Runte F; Barow P; Omari J; Abdelaziz ZM; Paustian L; Steurer S; Christina Tsourlakis M; Fisch M; Graefen M; Tennstedt P; Huland H; Michl U; Minner S; Sauter G; Simon R; Adam M; Schlomm T
    Int J Cancer; 2015 Nov; 137(10):2354-63. PubMed ID: 26009879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
    Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
    PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer.
    Ullman D; Dorn D; Rais-Bahrami S; Gordetsky J
    Urology; 2018 Mar; 113():59-70. PubMed ID: 29225123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
    Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
    Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
    Müller J; Ehlers A; Burkhardt L; Sirma H; Steuber T; Graefen M; Sauter G; Minner S; Simon R; Schlomm T; Michl U
    Int J Cancer; 2013 Mar; 132(6):1333-40. PubMed ID: 22886792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
    Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
    J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.